All In MedTech

Device Trial Radar · NCT04976530

Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)

Safe, Timely Antithrombotic Removal-Ticagrelor (STAR-T): Double-blind Randomized Study of Reduction in Bleeding by Ticagrelor Removal Via Intraop Use of DrugSorb-Antithrombotic Removal (ATR) in Cardiac Surgery Patients <2 Days of Drug Stop

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Aug 31, 2021

Primary completion

Aug 7, 2023

Study completion Aug 7, 2023

Sponsor

Lead sponsor
CytoSorbents, IncNot on our public-company list
Sponsor type
Industry
First posted
Jul 26, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-Antithrombotic Removal (ATR) system for intraoperative removal of ticagrelor in patients undergoing urgent cardiothoracic (CT) surgery with cardiopulmonary bypass (CPB).

Conditions

  • Hemorrhage, Surgical
  • Blood Loss, Surgical
  • Blood Loss, Postoperative
  • Hemorrhage Postoperative

Interventions

  • DrugSorb-ATR systemDevice

    Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit

  • Sham comparatorDevice

    Sham comparator in similar position to the investigative device, but NOT integrated into the cardiopulmonary (CPB) circuit

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Perioperative (Periop) Bleeding, Primary Effectiveness Composite Endpoint, Modified Intent to Treat (mITT) PopulationTime frame: Through the first 48hrs post-operation

3 more outcomes with a free account

Locations

29 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Davis Medical Center

    Sacramento, California

28 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.